77208@2x.jpg

EURTAC phase III trial

Response rates and PFS were significantly higher in erlotinib-treated European patients with EGFR Mut+ NSCLC compared with chemotherapy-treated patients. Erlotinib was also better tolerated.1,2

Study design and endpoints1

  • EURTAC was a randomised phase III trial that took place across 42 hospitals in France, Italy and Spain. 
  • The trial compared erlotinib versus standard chemotherapy as first-line treatment for EGFR Mut+ NSCLC.
page_8@2x.png

ECOG PS (Eastern Co-operative Oncology Group performance status)

Key Results

page_9_1@2x.png
Group 393.svg

Efficacy1

Patients who received erlotinib had significantly better response rates than patients receiving chemotherapy.

page_9_2@2x.png
Group 394.svg

Efficacy2

Patients who received erlotinib had significantly longer PFS than patients receiving chemotherapy.

page_10_1@2x.png
Group 393.svg

Efficacy3

Erlotinib-treated patients with pre-existing T790M mutations had significantly shorter median PFS than those who were T790M-negative (p=0.0185).

page_10_2@2x.png
Group 394.svg

Safety1

Erlotinib had a more favourable safety profile than chemotherapy in this patient population.

Please click here for further safety data